Filtered By:
Therapy: Endocrine Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 2859 results found since Jan 2013.
Abemaciclib as adjuvant treatment for high-risk early breast cancer
CONCLUSIONS: The results of the pivotal trial are sufficient to consider abemaciclib as adjuvant treatment for high-risk early breast cancer in highly selected patients. However, in order to the efficacy results present less uncertainty, we must wait for a evaluation later, in which we can have a mature determination at 3 years (with more patients at risk).PMID:37735004 | DOI:10.1016/j.farma.2023.08.006
Source: Farmacia Hospitalaria - September 21, 2023 Category: Drugs & Pharmacology Authors: Ganfornina Andrades Ana F énix Caballero Silvia Salguero Olid Alba Alegre Del-Rey Emilio Jes ús Source Type: research
Aggressive variant prostate cancer: A case report and literature review
CONCLUSION: We should reach consensus definitions of the AVPC and other androgen receptor-independent subtypes of PCA and develop new biomarkers to identify groups of high-risk variants. It is crucial to complete a puncture biopsy of the tumor or metastatic lesion as soon as possible in patients with advanced PCA who exhibit clinical features such as low Prostate-specific antigen levels, high carcinoembryonic antigen levels, and insensitivity to hormones to determine the pathological histological type and to create a more aggressive monitoring and treatment regimens.PMID:37731555 | PMC:PMC10507546 | DOI:10.12998/wjcc.v11.i26.6213
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xiang-Tao Weng Wen-Li Lin Qi-Man Pan Tao-Fen Chen Si-Yi Li Chi-Ming Gu Source Type: research
Oestrogen receptor-independent actions of oestrogen in cancer
Mol Biol Rep. 2023 Sep 20. doi: 10.1007/s11033-023-08793-8. Online ahead of print.ABSTRACTOestrogen, the primary female sex hormone, plays a significant role in tumourigenesis. The major pathway for oestrogen is via binding to its receptor [oestrogen receptor (ERα or β)], followed by nuclear translocation and transcriptional regulation of target genes. Almost 70% of breast tumours are ER + , and endocrine therapies with selective ER modulators (tamoxifen) have been successfully applied. As many as 25% of tamoxifen-treated patients experience disease relapse within 5 years upon completion of chemotherapy. In such cases, t...
Source: Molecular Biology Reports - September 21, 2023 Category: Molecular Biology Authors: Prarthana Gopinath Revathi Paramasivam Oviya Gopal Gopisetty Source Type: research
Aggressive variant prostate cancer: A case report and literature review
CONCLUSION: We should reach consensus definitions of the AVPC and other androgen receptor-independent subtypes of PCA and develop new biomarkers to identify groups of high-risk variants. It is crucial to complete a puncture biopsy of the tumor or metastatic lesion as soon as possible in patients with advanced PCA who exhibit clinical features such as low Prostate-specific antigen levels, high carcinoembryonic antigen levels, and insensitivity to hormones to determine the pathological histological type and to create a more aggressive monitoring and treatment regimens.PMID:37731555 | PMC:PMC10507546 | DOI:10.12998/wjcc.v11.i26.6213
Source: Clinical Prostate Cancer - September 21, 2023 Category: Cancer & Oncology Authors: Xiang-Tao Weng Wen-Li Lin Qi-Man Pan Tao-Fen Chen Si-Yi Li Chi-Ming Gu Source Type: research
Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast Cancer
In this report, we show TH ± E2 ± tamoxifen inhibits cell cycle control signaling, reduces apoptosis, and enhances cell proliferation, tumor growth, tamoxifen resistance, and clonal expansion. Mechanistically these changes involve numerous genes and pathways, including critical cell cycle regulatory proteins and genes identified using various molecular methods. These studies facilitate a greater mechanistic understanding of the biological and molecular impact of TH on SR+ BC.PMID:37723865 | DOI:10.1080/15384101.2023.2249702
Source: Cancer Control - September 19, 2023 Category: Cancer & Oncology Authors: Reema S Wahdan-Alaswad Susan M Edgerton Hyun Min Kim Aik Choon Tan Bryan R Haugen Bolin Liu Ann D Thor Source Type: research
The next-generation oral selective estrogen receptor degrader camizestrant (AZD9833) suppresses ER+ breast cancer growth and overcomes endocrine and CDK4/6 inhibitor resistance
In this study, we evaluated the preclinical pharmacology and efficacy of the next-generation oral SERD camizestrant (AZD9833) and assessed ER co-targeting strategies by combining camizestrant with CDK4/6 inhibitors (CDK4/6i) and PI3K/AKT/mTOR-targeted therapy in models of progression on CDK4/6i and/or ET. Camizestrant demonstrated robust and selective ER degradation, modulated ER-regulated gene expression, and induced complete ER antagonism and significant anti-proliferation activity in ESR1 wild-type (ESR1wt) and mutant (ESR1m) breast cancer cell lines and patient-derived xenograft (PDX) models. Camizestrant also delivere...
Source: Cell Research - September 19, 2023 Category: Cytology Authors: Mandy Lawson Natalie Cureton Susana Ros Azadeh Cheraghchi-Bashi-Astaneh Jelena Urosevic Sophie D'Arcy Oona Delpuech Michelle DuPont David I Fisher Eric T Gangl Hilary Lewis Dawn Trueman Neha Wali Stuart Charles Williamson Jennifer Moss Elodie Montaudon H Source Type: research
Artificial intelligence in breast imaging: potentials and challenges
Phys Med Biol. 2023 Sep 18. doi: 10.1088/1361-6560/acfade. Online ahead of print.ABSTRACTBreast cancer, which is the most common type of malignant tumor among humans, is a leading cause of death in females. Standard treatment strategies, including neoadjuvant chemotherapy, surgery, postoperative chemotherapy, targeted therapy, endocrine therapy, and radiotherapy, are tailored for individual patients. Such personalized therapies have tremendously reduced the threat of breast cancer in females. Furthermore, early imaging screening plays an important role in reducing the treatment cycle and improving breast cancer prognosis. ...
Source: Physics in Medicine and Biology - September 18, 2023 Category: Physics Authors: Jiawei Li Danli Sheng Jiangang Chen Chao You Shuai Liu Huixiong Xu Cai Chang Source Type: research
Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer
CONCLUSION: Our research demonstrates a closely relationship among CD47 and the immunological microenvironment of prostate cancer, and blocking CD47 can promote macrophages to phagocytosis of prostate cancer cells. Therefore, CD47 may provide novel strategies for potential immunotherapy of prostate cancer.PMID:37719086 | PMC:PMC10505079 | DOI:10.1155/2023/2473075
Source: Cell Research - September 18, 2023 Category: Cytology Authors: Qianqian Wang Chunxaing Feng Yuchun Chen Tianming Peng Yong Li Kunlin Wu Xiaoyong Pu Hanzhong Chen Jiumin Liu Source Type: research
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Surg Oncol Clin N Am. 2023 Oct;32(4):663-673. doi: 10.1016/j.soc.2023.05.011. Epub 2023 Jun 15.ABSTRACTDCIS detection has increased dramatically since the introduction of screening mammography. Current guidance concordant care recommends surgical intervention for all patients with DCIS, followed by radiation and/or endocrine therapy for some. Adjuvant therapies after surgical excision have reduced recurrence rates but not breast cancer mortality. Given the lack of evidence of current treatment regimens and the morbidity associated with these treatments, there is concern that DCIS is over-treated. Active surveillance may be...
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Sydney M Record Eun-Sil Shelley Hwang Akiko Chiba Source Type: research
Prognostic model of ER-positive, HER2-negative breast cancer predicted by clinically relevant indicators
CONCLUSION: To generate nomograms that predicted DFS and OS, independent predictors of DFS in ER-positive/HER2-negative breast cancer patients were chosen. The nomograms successfully stratified patients into prognostic categories and worked well in both internal validation and external validation.PMID:37713046 | DOI:10.1007/s12094-023-03316-0
Source: Clinical Breast Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Xinming Song Pintian Wang Ruiling Feng Mandika Chetry E Li Xiaohua Wu Zewa Liu Shasha Liao Jing Lin Source Type: research
How to Navigate the Treatment Spectrum from Multimodality Therapy to Observation Alone for ductal carcinoma in situ
Surg Oncol Clin N Am. 2023 Oct;32(4):663-673. doi: 10.1016/j.soc.2023.05.011. Epub 2023 Jun 15.ABSTRACTDCIS detection has increased dramatically since the introduction of screening mammography. Current guidance concordant care recommends surgical intervention for all patients with DCIS, followed by radiation and/or endocrine therapy for some. Adjuvant therapies after surgical excision have reduced recurrence rates but not breast cancer mortality. Given the lack of evidence of current treatment regimens and the morbidity associated with these treatments, there is concern that DCIS is over-treated. Active surveillance may be...
Source: Clinical Genitourinary Cancer - September 15, 2023 Category: Cancer & Oncology Authors: Sydney M Record Eun-Sil Shelley Hwang Akiko Chiba Source Type: research
Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi study
DISCUSSION: ET in combination with a CDK4/6 inhibitor is the preferred frontline treatment for HR+/HER2- aBC in the Nordics. The observed discrepancy between current guidelines and clinical practice could be due to differences in the reimbursement of novel treatments in the Nordics. Collaborative research efforts are warranted for topics that lack consensus.PMID:37713138 | DOI:10.1080/0284186X.2023.2254475
Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: J ürgen Geisler Peeter Karihtala Malgorzata Tuxen Antonis Valachis Delphi Panellist Group Barbro Holm Source Type: research
